S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Here’s What’s Driving the Price of Carvana Higher
Tesla: How and Why It Gets To $300
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Here’s What’s Driving the Price of Carvana Higher
Tesla: How and Why It Gets To $300
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Here’s What’s Driving the Price of Carvana Higher
Tesla: How and Why It Gets To $300
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Here’s What’s Driving the Price of Carvana Higher
Tesla: How and Why It Gets To $300
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Top-Rated StocksTop-Rated
NASDAQ:IPSC

Century Therapeutics (IPSC) Earnings Date, Estimates & Call Transcripts

$3.20
+0.04 (+1.27%)
(As of 06/6/2023 ET)
Compare
Today's Range
$3.13
▼
$3.30
50-Day Range
$2.91
▼
$3.53
52-Week Range
$2.81
▼
$14.00
Volume
94,231 shs
Average Volume
77,066 shs
Market Capitalization
$190.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
Aug. 10Estimated
Actual EPS
(Mar. 16)
-$0.55 Beat By $0.05
Consensus EPS
(Mar. 16)
-$0.60
Last Year's Q1 EPS
(3/17/2022)
-$0.24
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

IPSC Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

IPSC Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Century Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20234($0.64)($0.33)($0.52)
Q2 20234($0.69)($0.34)($0.53)
Q3 20234($0.72)($0.35)($0.54)
Q4 20234($0.79)($0.36)($0.57)
FY 202316($2.84)($1.38)($2.16)
Q1 20241($0.48)($0.48)($0.48)
Q2 20241($0.47)($0.47)($0.47)
Q3 20241($0.46)($0.46)($0.46)
Q4 20241($0.46)($0.46)($0.46)
FY 20244($1.87)($1.87)($1.87)

IPSC Earnings Date and Information

Century Therapeutics last issued its quarterly earnings results on March 16th, 2023. The reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.05. The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $2.80 million. Century Therapeutics has generated ($2.15) earnings per share over the last year (($2.15) diluted earnings per share). Earnings for Century Therapeutics are expected to grow in the coming year, from ($2.07) to ($1.95) per share. Century Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 10th, 2023 based off prior year's report dates.

Century Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/10/2023
(Estimated)		        
5/11/2023Q1 2023($0.53)($0.53)($0.53)$2.26 million$1.72 million
3/16/2023Q4 2022($0.60)($0.55)+$0.05($0.55)$2.80 million$0.52 million
11/10/2022Q3 2022($0.59)($0.53)+$0.06($0.53)$1.57 million$2.22 million
8/11/2022Q2 2022($0.50)($0.54)($0.04)($0.54)$1.20 million$1.40 million
5/16/2022Q1 2022($0.45)($0.66)($0.21)($0.66)$20.00 million$1.06 million
3/17/2022Q4 2021($0.46)($0.24)+$0.22($0.24)
11/10/20219/30/2021($0.40)($0.48)($0.08)($0.48)
8/12/20216/30/2021($0.40)($1.93)($1.53)($1.93)












Century Therapeutics Earnings - Frequently Asked Questions

When is Century Therapeutics's earnings date?

Century Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 10th, 2023 based off last year's report dates. Learn more on IPSC's earnings history.

Did Century Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Century Therapeutics (NASDAQ:IPSC) reported ($0.55) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.60) by $0.05. Learn more on analysts' earnings estimate vs. IPSC's actual earnings.

How much revenue does Century Therapeutics generate each year?

Century Therapeutics (NASDAQ:IPSC) has a recorded annual revenue of $5.20 million.

How much profit does Century Therapeutics generate each year?

Century Therapeutics (NASDAQ:IPSC) has a recorded net income of -$130.93 million. IPSC has generated -$2.15 earnings per share over the last four quarters.

What is Century Therapeutics's EPS forecast for next year?

Century Therapeutics's earnings are expected to grow from ($2.07) per share to ($1.95) per share in the next year.

More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:IPSC) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -